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Coffee consumption and health: umbrella review  
of meta-analyses of multiple health outcomes
Robin Poole,1 Oliver J Kennedy,1 Paul Roderick,1 Jonathan A Fallowfield,2 Peter C Hayes,2  
Julie Parkes1
ABSTRACT
OBJECTIVES
To evaluate the existing evidence for associations 
between coffee consumption and multiple health 
outcomes.
DESIGN
Umbrella review of the evidence across meta-analyses 
of observational and interventional studies of coffee 
consumption and any health outcome.
DATA SOURCES
PubMed, Embase, CINAHL, Cochrane Database of 
Systematic Reviews, and screening of references.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES
Meta-analyses of both observational and 
interventional studies that examined the associations 
between coffee consumption and any health outcome 
in any adult population in all countries and all 
settings. Studies of genetic polymorphisms for coffee 
metabolism were excluded.
RESULTS
The umbrella review identified 201 meta-analyses 
of observational research with 67 unique health 
outcomes and 17 meta-analyses of interventional 
research with nine unique outcomes. Coffee 
consumption was more often associated with benefit 
than harm for a range of health outcomes across 
exposures including high versus low, any versus 
none, and one extra cup a day. There was evidence of 
a non-linear association between consumption and 
some outcomes, with summary estimates indicating 
largest relative risk reduction at intakes of three to 
four cups a day versus none, including all cause 
mortality (relative risk 0.83, 95% confidence interval 
0.83 to 0.88), cardiovascular mortality (0.81, 0.72 
to 0.90), and cardiovascular disease (0.85, 0.80 to 
0.90). High versus low consumption was associated 
with an 18% lower risk of incident cancer (0.82, 0.74 
to 0.89). Consumption was also associated with a 
lower risk of several specific cancers and neurological, 
metabolic, and liver conditions. Harmful associations 
were largely nullified by adequate adjustment for 
smoking, except in pregnancy, where high versus 
low/no consumption was associated with low birth 
weight (odds ratio 1.31, 95% confidence interval 
1.03 to 1.67), preterm birth in the first (1.22, 1.00 to 
1.49) and second (1.12, 1.02 to 1.22) trimester, and 
pregnancy loss (1.46, 1.06 to 1.99). There was also 
an association between coffee drinking and risk of 
fracture in women but not in men.
CONCLUSION
Coffee consumption seems generally safe within usual 
levels of intake, with summary estimates indicating 
largest risk reduction for various health outcomes at 
three to four cups a day, and more likely to benefit 
health than harm. Robust randomised controlled 
trials are needed to understand whether the observed 
associations are causal. Importantly, outside of 
pregnancy, existing evidence suggests that coffee 
could be tested as an intervention without significant 
risk of causing harm. Women at increased risk of 
fracture should possibly be excluded.
Introduction
Coffee is one of the most commonly consumed 
beverages worldwide.1 As such, even small individual 
health effects could be important on a population 
scale. There have been mixed conclusions as to 
whether coffee consumption is beneficial or harmful 
to health, and this varies between outcomes.2 Roasted 
coffee is a complex mixture of over 1000 bioactive 
compounds,3 some with potentially therapeutic 
antioxidant, anti-inflammatory, antifibrotic, or 
anticancer effects that provide biological plausibility 
for recent epidemiological associations. Key active 
compounds include caffeine, chlorogenic acids, and 
the diterpenes, cafestol and kahweol. The biochemistry 
of coffee has been documented extensively elsewhere.4 
Coffee undergoes a chemical metamorphosis from the 
unroasted green bean, and the type of bean (Arabica 
versus Robusta), degree of roasting, and preparation 
method including coffee grind setting and brew 
type, will all have an influence on the biochemical 
composition of the final cup.5-7 An individual’s 
genotype and gut microbiome will then determine the 
bioavailability and type of coffee metabolites to which 
that individual is exposed.8
Existing research has explored the associations 
between coffee as an exposure and a range of outcomes 
including all cause mortality, cancer, and diseases 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Coffee is highly consumed worldwide and could have positive health benefits, 
especially in chronic liver disease
Beneficial or harmful associations of drinking coffee seem to vary between health 
outcomes of interest
Understanding associations of coffee and health is important, especially in 
relation to exploring harmful associations, before interventional research is 
conducted
WhAT ThIS STudy AddS
Coffee drinking seems safe within usual patterns of consumption, except during 
pregnancy and in women at increased risk of fracture
Existing evidence is observational and of lower quality, and randomised 
controlled trials are needed
A future randomised controlled trial in which the intervention is increasing coffee 
consumption would be unlikely to result in significant harm to participants
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of the cardiovascular, metabolic, neurological, 
musculoskeletal, gastrointestinal, and liver systems, 
as well as outcomes associated with pregnancy. Most 
of this research has been observational in design, 
relying on evidence from cross sectional, case-
control, or cohort studies, and often summarised 
by outcome through systematic review and meta-
analysis. We have previously explored the relation 
between coffee consumption and liver cirrhosis9 and 
hepatocellular carcinoma10 and found significant 
beneficial associations for both. Observational 
evidence can suggest association but is unable to make 
causative claims, though methods based on Mendelian 
randomisation are less prone to confounding. 
Interventional research, ideally in the form of 
randomised controlled trials, is essential before we can 
fully understand coffee’s potential to prevent specific 
health outcomes.
Before an interventional approach is taken, 
however, it is important to systematically assess 
the totality of higher level evidence of the effects of 
coffee consumption on all health outcomes. This 
approach can help contextualise the magnitude of the 
association across health outcomes and importantly 
assess the existing research for any harm that could be 
associated with increased consumption. To assimilate 
the vast amount of research available on coffee 
consumption and health outcomes, we performed an 
umbrella review of existing meta-analyses.
Methods
Umbrella review methods
Umbrella reviews systematically search, organise, and 
evaluate existing evidence from multiple systematic 
reviews and/or meta-analyses on all health outcomes 
associated with a particular exposure.11 We conducted 
a review of coffee consumption and multiple health 
outcomes by systematically searching for meta-
analyses in which coffee consumption was all or part of 
the exposure of interest or where coffee consumption 
had been part of a subgroup analysis. Consumption, 
usually measured by cups a day, lends itself to 
combined estimates of effect in meta-analyses and we 
decided to include only meta-analyses in the umbrella 
review. Specifically, we excluded systematic reviews 
without meta-analysis.
Literature search
We searched PubMed, Embase, CINAHL, and 
the Cochrane Database of Systematic Reviews 
from inception to July 2017 for meta-analyses of 
observational or interventional studies that investigated 
the association between coffee consumption and 
any health outcome. We used the following search 
strategy: (coffee OR caffeine) AND (systematic review 
OR meta-analysis) using truncated terms for all fields, 
and following the SIGN guidance recommended search 
terms for systematic reviews and meta-analyses.12 Two 
researchers (RP and OJK) independently screened 
the titles and abstracts and selected articles for full 
text review. They then independently reviewed full 
text articles for eligibility. A third researcher, PR, 
arbitrated any differences that could not be resolved by 
consensus. We also performed a manual search of the 
references of eligible articles.
Eligibility criteria and data extraction
Articles were eligible if they were meta-analyses and 
had been conducted with systematic methods. We 
included meta-analyses of both observational (cohort, 
case-control, and cross sectional with binary outcomes) 
and interventional studies (randomised controlled 
trials). Meta-analyses were included when they pooled 
any combination of relative risks, odds ratios, relative 
rates, or hazard ratios from studies comparing the 
same exposure with the same health outcome. Articles 
were included if the coffee exposure was in any adult 
population of any ethnicity or sex in all countries and 
all settings. Participants could be healthy or have pre-
existing illness, be pregnant, and be habitual or non-
habitual coffee drinkers. Articles were also included 
when the exposure was total coffee or coffee separated 
into caffeinated and decaffeinated status. We excluded 
meta-analyses of total caffeine exposure and health 
outcomes unless we could extract caffeine exposure 
from coffee separately from a subgroup analysis. Coffee 
contains numerous biologically active ingredients that 
can interact to produce unique health effects that could 
be different to effects of caffeine from other sources. 
Additionally, we were interested in coffee, rather 
than caffeine, as a potential intervention in a future 
randomised controlled trial. All health outcomes for 
which coffee consumption had been investigated as 
the exposure of interest were included, except studies 
of genetic polymorphisms for coffee metabolism. 
We included any study with comparisons of coffee 
exposure, including high versus low, any versus 
none, and any linear or non-linear dose-responses. If 
an article presented separate meta-analyses for more 
than one health outcome, we included each of these 
separately.
RP and OJK independently extracted data from 
eligible articles. From each meta-analysis, they 
extracted the first author, journal, year of publication, 
outcome(s) of interest, populations, number of studies, 
study design(s), measure(s) of coffee consumption, 
method(s) of capture of consumption measurement, 
consumption type(s), and sources of funding. For 
each eligible article they also extracted study specific 
exposure categories as defined by authors, risk 
estimates and corresponding confidence intervals, 
number of cases and controls (case-control studies), 
events, participant/person years and length of follow-
up (cohort studies) or numbers in intervention and 
control groups (randomised controlled trials), type of 
risk used for pooling, and type of effect model used in the 
meta-analysis (fixed or random). When a meta-analysis 
considered a dose-response relation and published 
a P value for non-linearity this was also extracted. 
Finally, we extracted any estimate of variance between 
studies (τ2), estimates of the proportion of variance 
reflecting true differences in effect size (I2), and any 
RESEARCH
the bmj | BMJ 2017;359:j5024 | doi: 10.1136/bmj.j5024 3
presented measure of publication bias. Any difference 
in extracted data between the two researchers was 
resolved by consensus.
Assessment of methodological quality of included 
studies and quality of evidence
We assessed methodological quality of meta-
analyses using AMSTAR,13 a measurement tool 
to assess systematic reviews. AMSTAR has been 
shown to be a reliable and valid tool for quality 
assessment of systematic reviews and meta-analyses 
of both interventional and observational research.13 14 
AMSTAR includes ratings for quality in the search, 
analysis, and transparency of a meta-analysis. For the 
rating item for methodological quality in the analysis, 
we downgraded any study that had used a fixed 
rather than a random effects model for producing a 
summary estimate. We considered the random effects 
model the most appropriate to be used in pooling 
estimates because the heterogeneity in study designs, 
populations, methods of coffee preparation, and cup 
sizes meant we would not expect a single true effect 
size common to all studies.
We used the GRADE (Grading of Recommendations, 
Assessment, Development and Evaluation) working 
group classification to assess the quality of evidence for 
each outcome included in the umbrella review.15 The 
GRADE approach categorises evidence from systematic 
reviews and meta-analyses into “high,” “moderate,” 
“low,” or “very low” quality. Study design dictates 
baseline quality of the evidence but other factors can 
decrease or increase the quality level. For example, 
unexplained heterogeneity or high probability of 
publication bias could decrease the quality of the 
evidence, and a large magnitude of effect or dose-
response gradient could increase it.
Method of analysis
We reanalysed each meta-analysis using the 
DerSimonian and Laird random effects model, which 
takes into account variance between and within 
studies.16 We did this through extraction of exposure 
and outcome data, as published in each meta-analysis 
article, when these were available in sufficient detail. 
We did not review the primary study articles included 
in each meta-analysis. As is conventional for risk ratios, 
we computed the summary estimates using the log 
scale to maintain symmetry in the analysis and took the 
exponential to return the result to the original metric. 
We produced the τ2 statistic as an estimate of true 
variation in the summary estimate and the I2 statistic 
as an estimate of proportion of variance reflecting true 
differences in effect size. We also calculated an estimate 
for publication bias with Egger’s regression test17 for 
any reanalyses that included at least 10 studies. A P 
value <0.1 was considered significant for Egger’s test. 
We did not reanalyse any of the dose-response meta-
analyses because of the scarcity of published estimates 
for number of cases and controls/participants and 
estimates for each dose of coffee exposure needed for 
a dose-response analysis. When we were interested in 
the apparent effect modification by sex, we conducted 
a test of interaction using the method published by 
Altman and Bland.18
We constructed forest plots from the extracted and/or 
reanalysed data to display three categories of exposure 
for any health outcome (high versus low (or none), 
any (regular) versus none, and one extra cup a day 
(relative to none) in which that category of exposure 
was available. Each article presented a meta-analysis 
with one or more of these exposure categories or 
calculated combined estimates for a range of cups a day 
exposures for which a non-linear dose-response had 
been identified. A single health outcome per category 
of exposure was included in a forest plot representing 
the most recent study available. If two or more studies 
were published within the same 24 month period for 
the same category of exposure and same outcome, we 
selected the one with the highest number of cohort 
studies. We used a final tier of highest AMSTAR score 
if two studies published in the same period had the 
same number of cohort studies. When a meta-analysis 
included both cohort and case-control studies and 
when subgroup analysis was published by study 
design, we selected the cohort design subanalysis for 
inclusion in the summary forest plots or reanalysed 
when possible. This was deemed to represent the 
higher form of evidence as it was not affected by recall 
and selection bias and was less likely to be biased by 
reverse causality that can affect case-control studies. 
When linear dose-response analyses presented results 
for two or three extra cups a day we converted this 
to one extra cup a day by taking the square or cube 
root respectively (A Crippa, personal communication, 
2017). We included heterogeneity, represented by 
the τ2 statistic, and publication bias, represented by 
Egger’s test. When we could not reanalyse data from a 
meta-analysis we included summary data as extracted 
from the meta-analysis article and whichever measure 
of heterogeneity or publication bias, if any, was 
available.
Patient involvement
This study was informed by feedback from  a patient 
and public involvement focus  group  and from 
an independent  survey of  patients with chronic 
liver  disease in secondary care. This preliminary 
work showed enthusiasm from patients in participating 
in a randomised controlled trial involving coffee as an 
intervention and in finding out more information about 
the wider benefits and potential harms of increasing 
coffee intake. Furthermore, the results of this umbrella 
review were also  disseminated during a recent focus 
group  session that had been arranged to gather 
opinions regarding the acceptability of  qualitative 
research to investigate patterns of coffee drinking in 
people with non-alcoholic fatty liver disease.
Results
Figure 1 shows the results of the systematic search 
and selection of eligible studies. The search yielded 
201 meta-analyses of observational research in 135 
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articles with 67 unique outcomes and 17 meta-
analyses of randomised-controlled trials in six articles 
with nine unique outcomes. The median number of 
meta-analyses per outcome for observational research 
was two (interquartile range 1-4, range 1-11). Twenty 
two outcomes had only a single meta-analysis. For 
meta-analyses of randomised controlled trials, 
outcomes were limited to systolic and diastolic blood 
pressure, total cholesterol, low density lipoprotein 
(LDL) cholesterol, high density lipoprotein (HDL) 
cholesterol, triglyceride, and three outcomes related 
to pregnancy: preterm birth, small for gestational 
age, and birth weight. Figures 2-4 show summary 
data for the meta-analyses selected as the highest 
form of evidence for coffee consumption and each 
outcome for high versus low (or none) or any (regular) 
versus no consumption and one extra cup a day coffee 
consumption. These show risk estimates for each 
outcome from 10 most harmful associations to the 10 
most beneficial associations. Full versions of the forest 
plots are available in appendix 1. Figure 5 shows 
the associations with consumption of decaffeinated 
coffee across the three exposure categories, and 
figures 6-9 show interventional exposures for coffee 
versus control for outcomes of blood pressure, lipids, 
and outcomes related to pregnancy. Risk estimates 
across different exposure categories for each outcome, 
Articles with meta-analysis of
randomised controlled trials (n=6)
Articles with meta-analysis of
observational studies (n=135)
Meta-analyses of 9 unique outcomes (n=17)Meta-analyses of 67 unique outcomes (n=201)
Duplicates (n=634)Unique titles (n=1180)
Manual search through references (n=4)
Eligible full text articles (n=141)
Excluded on rst pass (n=917)Eligible titles and abstracts (n=263)
Cochrane (n=31)CINHAL (n=440)Embase (n=872)PubMed (n=471)
Excluded (n=126):
  Review without meta-analysis (n=49)
  Caeine not coee (n=33)
  Conference abstract (n=10)
  Wrong exposure or design (n=5)
  Coee data not meta-analysed (n=5)
  Duplicate (n=21)
  Not English language (n=2)
  Letter (n=1)
Fig 1 | Flowchart of selection of studies for inclusion in umbrella review on coffee 
consumption and health 
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  Pregnancy loss23
  Rheumatoid arthritis74 75
  Low birth weight82
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  3rd trimester preterm birth83
  Oral cle malformation85
10 most benecial
  Type 2 diabetes21‡
  Oral cancer39
  Cirrhosis63
  Renal stones66
  Parkinson’s disease22
  Leukaemia38
  Post-MI mortality30
  Gout67
  Liver cancer43
  Chronic liver disease43
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Fig 2 | High versus low coffee consumption and associations with multiple health outcomes. Estimates are relative risks and effect models are 
random unless noted otherwise. For type 2 diabetes, P value was significant for non-linearity. No of events/total for leukaemia could not be split 
from other outcomes. All estimates were from our own reanalysis apart from preterm birth in first and third trimester and leukaemia
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Fig 3 | Any versus no coffee consumption and associations with multiple health outcomes. Estimates are relative risks and effect models are random 
unless noted otherwise. All estimates were from our own reanalysis apart from acute leukaemia, urinary tract cancer, and colorectal cancer
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Fig 4 | Consumption of one extra cup of coffee a day and associations with multiple health outcomes. Estimates are relative risks and effect models 
are random unless noted otherwise. No dose response analyses were re-analysed
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grouped by body system, are available in figures A-I in 
appendix 2.
The most commonly studied exposure was high 
versus low (or no) coffee consumption, and significance 
was reached for beneficial associations with 19 health 
outcomes and harmful associations with six. The 34 
remaining outcomes were either negatively or positively 
associated but without reaching significance. Similarly, 
in comparisons of any (regular) with no consumption, 
significance was reached for beneficial associations 
with 11 outcomes and harmful associations with 
three. Finally, for one extra cup a day, significance was 
reached for beneficial associations with 11 outcomes 
and harmful associations with three. Eight out of 
18 studies19-27 that tested for non-linearity for the 
association with one extra cup a day found significant 
evidence for this.
All cause mortality
In the most recent meta-analysis, by Grosso and 
colleagues, the highest exposure category (seven cups 
a day) of a non-linear dose-response analysis was 
associated with a 10% lower risk of all cause mortality 
(relative risk 0.90, 95% confidence interval 0.85 to 
0.96),28 but summary estimates indicated that the 
largest reduction in relative risk was associated with 
the consumption of three cups a day (0.83, 0.83 to 
0.88) compared with no consumption. Stratification by 
sex produced similar results. In a separate article, and 
despite a significant test for non-linearity (P<0.001), 
authors performed a linear dose-response analysis 
and found consumption of one extra cup a day was 
associated with a 4% lower risk of all cause mortality 
(0.96, 0.94 to 0.97).27 The apparently beneficial 
association between coffee and all cause mortality was 
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Fig 5 | Consumption of decaffeinated coffee and associations with multiple health outcomes. Estimates are relative risks and effect models are 
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consistent across all earlier meta-analyses. High versus 
low intake of decaffeinated coffee was also associated 
with lower all cause mortality, with summary estimates 
indicating largest benefit at three cups a day (0.83, 
0.85 to 0.89)28 in a non-linear dose-response analysis.
Cardiovascular disease
Coffee consumption was consistently associated with a 
lower risk of mortality from all causes of cardiovascular 
disease, coronary heart disease, and stroke in a non-
linear relation, with summary estimates indicating 
largest reduction in relative risk at three cups a day.28 
Compared with non-drinkers, risks were reduced by 
19% (relative risk 0.81, 95% confidence interval 0.72 
to 0.90) for mortality from cardiovascular disease, 16% 
(0.84, 0.71 to 0.99) for mortality from coronary heart 
disease, and 30% (0.70, 0.80 to 0.90) for mortality from 
stroke, at this level of intake. Increasing consumption 
to above three cups a day was not associated with harm, 
but the beneficial effect was less pronounced, and the 
estimates did not reach significance at the highest 
intakes. In stratification by sex within the same article, 
women seemed to benefit more than men at higher 
levels of consumption for outcomes of mortality from 
cardiovascular disease and coronary heart disease but 
less so from stroke.28 In a separate meta-analysis, that 
did not test for non-linearity, an exposure of one extra 
cup a day was associated with a 2% reduced risk of 
cardiovascular mortality (0.98, 0.95 to 1.00).29 There 
was also evidence of benefit in relation to high versus 
low coffee consumption after myocardial infarction 
and lower risk of mortality (hazard ratio 0.55, 95% 
confidence interval 0.45 to 0.67).30
Coffee consumption was non-linearly associated 
with a lower risk of incident cardiovascular disease 
(relative risk 0.85, 95% confidence interval 0.80 
to 0.90), coronary heart disease (0.90, 0.84 to 
0.97), and stroke (0.80, 0.75 to 0.86), with these 
summary estimates indicating the largest benefits at 
consumptions of three to five cups a day.19 There was 
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no apparent modification of this association by sex. 
Risk was also lower for the comparison of high versus 
low consumption but did not reach significance. Any 
versus no consumption was also associated with 
a beneficial effect on stroke (0.89, 0.81 to 0.97).31 
High versus low coffee and one extra cup a day were 
both associated with a lower risk of atrial fibrillation 
but neither reached significance.32 There was no 
significant association between consumption and 
risk of venous thromboembolism.33 There was a non-
linear association between consumption and heart 
failure, with summary estimates indicating the largest 
benefit at four cups a day (0.89, 0.81 to 0.99),24 with 
a slightly higher risk of heart failure at consumption 
of 10 or more cups a day (1.01, 0.90 to 1.14), though 
this did not reach significance.24 For hypertension, 
there were no significant estimates of risk at any 
level of consumption in a non-linear dose-response 
analysis34 nor in comparisons of any versus none.35 
There was no clear benefit in comparisons of high with 
low decaffeinated consumption and cardiovascular 
disease.19
In a meta-analysis of randomised controlled trials, 
coffee consumption had a marginally beneficial 
association with blood pressure when compared with 
control but failed to reach significance.35 Consumption 
does, however, seem consistently associated with 
unfavourable changes to the lipid profile, with mean 
differences in total cholesterol (0.19 mmol/L, 95% 
confidence interval 0.10 mmol/L to 0.28 mmol/L),36 
low density lipoprotein cholesterol (0.14 mmol/L, 
0.04 mmol/L to 0.25 mmol/L),36 and triglyceride (0.14 
mmol/L, 0.04 mmol/L to 0.24 mmol/L)36 higher in 
the coffee intervention arms than the control arms 
(1 mmol/L cholesterol = 38.6 mg/dL, 1 mmol/L 
triglyceride = 88.5 mg/dL37). Consumption was 
associated with lower high density cholesterol (−0.002 
mmol/L, −0.02 mmol/L to 0.54 mol/L), but this did 
not reach significance. The increases in cholesterol 
concentration were mitigated with filtered coffee, with 
a marginal rise in concentration (mean difference 0.09 
mmol/L, 0.02 to 0.17)36 and no significant changes 
to low density lipoprotein cholesterol or triglycerides 
compared with unfiltered (boiled) coffee. Similarly, 
decaffeinated coffee seemed to have negligible effect 
on the lipid profile.36
Cancer
A meta-analysis of 40 cohort studies showed a 
lower incidence of cancer for high versus low coffee 
consumption (relative risk 0.82, 95% confidence 
interval 0.74 to 0.89),38 any versus no consumption 
(0.87, 0.82 to 0.92),38 and one extra cup a day (0.97, 
0.96 to 0.98).38 In a separate article, in non-smokers 
there was a 2% lower risk of mortality from cancer 
for exposure of one extra cup a day (0.98, 0.96 to 
1.00).28 For smokers, the article provided results only 
from a non-linear analysis, and the risk of mortality 
from cancer increased at all levels of coffee exposure, 
reaching significance above four cups a day.
High versus low coffee consumption was associated 
with a lower risk of prostate cancer,39 endometrial 
cancer,40 melanoma,41 oral cancer,39 leukaemia,38 
non-melanoma skin cancer,42 and liver cancer.43 
For prostate,44 endometrial,39 melanoma,45 and 
liver cancer43 there were also significant linear dose-
response relations indicating benefit.
There were consistent harmful associations for 
coffee consumption with lung cancer for high versus 
low consumption (odds ratio 1.59, 95% confidence 
interval 1.26 to 2.00),46 any versus none (relative risk 
1.28, 1.12 to 1.47),47 and one extra cup a day (1.04, 
1.03 to 1.05).47 The effect was diminished, however, in 
studies that adjusted for smoking, and the association 
was not seen in never smokers. In the most recent 
meta-analysis, any versus no consumption in people 
who had never smoked was associated with an 8% 
lower risk of lung cancer (0.92, 0.75 to 1.10),47 and 
in studies that adjusted for smoking the risk estimate 
was reduced (1.03, 0.95 to 1.12)47 compared with the 
overall analysis, and neither reached significance. In 
contrast, a meta-analysis of two studies showed that 
high versus low consumption of decaffeinated coffee 
was associated with a lower risk of lung cancer.48
A single meta-analysis found an association 
between any versus no coffee consumption and higher 
risk of any urinary tract cancer (odds ratio 1.18, 95% 
confidence interval 1.01 to 1.38).49 In other meta-
analyses of cohort studies of bladder cancer and renal 
cancer separately, however, associations did not reach 
significance.39
No significant association was found between coffee 
consumption and gastric,39 50 51 colorectal,20 39 52 colon,20 52 
rectal,20 52 ovarian,39 53 thyroid,54 55 breast,38  39 56 
pancreatic,57 oesophageal,39 58 or laryngeal cancers59 
and lymphoma39 60 or glioma.61
Liver and gastrointestinal outcomes
In addition to beneficial associations with liver cancer, 
all categories of coffee exposure were associated with 
lower risk for a range of liver outcomes. Any versus 
no coffee consumption was associated with a 29% 
lower risk of non-alcoholic fatty liver disease (relative 
risk 0.71, 0.60 to 0.85),62 a 27% lower risk for liver 
fibrosis (odds ratio 0.73, 0.56 to 0.94),63 and a 39% 
lower risk for liver cirrhosis (0.61, 0.45 to 0.84).63 
Coffee consumption was also associated with a lower 
risk of cirrhosis with high versus low consumption 
(0.69, 0.44 to 1.07)63 and one extra cup a day (relative 
risk 0.83, 0.78 to 0.88).9 Exposure to one extra cup a 
day was also significantly associated with a lower risk 
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of mortality from cirrhosis (0.74, 0.59 to 0.86).9 In a 
single article,43 for meta-analyses of consumption and 
chronic liver disease, high versus low (0.35, 0.22 to 
0.56), any versus none (0.62, 0.47 to 0.82), and one 
extra cup a day (0.74, 0.65 to 0.83) were all associated 
with benefit.
Coffee consumption was also consistently associated 
with significantly lower risk of gallstone disease.25 
A non-linear dose response was also apparent, 
though risk sequentially reduced as consumption 
increased from two to six cups a day.25 High versus low 
consumption was associated with a marginally higher 
risk of gastro-oesophageal reflux disease, but this did 
not reach significance.64
Metabolic disease
Coffee consumption was consistently associated with 
a lower risk of type 2 diabetes for high versus low 
consumption (relative risk 0.70, 95% confidence 
interval 0.65 to 0.75)21 and one extra cup a day (0.94, 
0.93 to 0.95).65 There was some evidence for a non-
linear dose-response, but the risk was still lower for 
each dose of increased consumption between one and 
six cups.21 Consumption of decaffeinated coffee also 
seemed to have similar associations of comparable 
magnitude.21 For metabolic syndrome high versus low 
coffee consumption was associated with 9% lower risk 
(0.91, 0.86 to 0.95).26 High versus low consumption 
was also significantly associated with a lower risk of 
renal stones66 and gout.67
Renal outcomes
Coffee consumption of any versus none was associated 
with a lower risk of urinary incontinence68 and chronic 
kidney disease,69 but neither association reached 
significance, and the meta-analyses included cross 
sectional studies.
Musculoskeletal outcomes
There is inconsistency in the association between 
coffee consumption and musculoskeletal outcomes. 
There were no significant overall associations between 
high versus low consumption or one extra cup a day 
coffee and risk of fracture70 71 or hip fracture.72 73 In 
subgroup analysis by sex, however, high versus low 
consumption was associated with an increased risk of 
fracture in women (relative risk 1.14, 95% confidence 
interval 1.05 to 1.24) and a decreased risk in men (0.76, 
0.62 to 0.94)70 (test of interaction (ratio of relative risks 
(women:men) 1.50, 1.20 to 1.88; P<0.001). There was 
a non-significant association between high versus low 
consumption and risk of hip fracture in a subgroup 
analysis of women (relative risk 1.27, 0.94 to 1.72)72 
but not men (0.53, 0.38 to 1.00)72 (test of interaction 
2.40, 1.35 to 4.24; P<0.01). For consumption of one 
extra cup a day there was also an association with 
increased risk of fracture in women (relative risk 
1.05, 1.02 to 1.07)71 but a lower risk in men (0.91, 
0.87 to 0.95)71 (test of interaction 1.15, 1.10 to 1.21; 
P<0.001). These results suggest that sex might be a 
significant effect modifier in the association between 
coffee and risk of fracture. Associations were also 
found for total and decaffeinated coffee consumption 
and higher risk of rheumatoid arthritis,74 75 but neither 
reached significance.
Neurological outcomes
Coffee consumption was consistently associated 
with a lower risk of Parkinson’s disease, even after 
adjustment for smoking, and across all categories of 
exposure.22 76 77 Decaffeinated coffee was associated 
with a lower risk of Parkinson’s disease, which did not 
reach significance.22 Consumption had a consistent 
association with lower risk of depression78 79 and 
cognitive disorders, especially for Alzheimer’s disease 
(relative risk 0.73, 95% confidence interval 0.55 to 
0.97)80 in meta-analyses of cohort studies.
Gynaecological outcomes
Exposures of any versus no coffee consumption were 
associated with a higher risk of endometriosis but did 
not reach significance.81
Antenatal exposure to coffee
There is some consistency in evidence for harmful 
associations of coffee consumption with different 
outcomes related to pregnancy. High versus low 
consumption was associated with a higher risk of 
low birth weight (odds ratio 1.31, 95% confidence 
interval 1.03 to 1.67),82 pregnancy loss (1.46, 1.06 
to 1.99),23 first trimester preterm birth (1.22, 1.00 
to 1.49),83 and second trimester preterm birth (1.12, 
1.02 to 1.22).83 No significant association, however, 
was found for any category of coffee consumption and 
third trimester preterm birth,83 neural tube defects,84 
and congenital malformations of the oral cleft85 or 
cardiovascular system.85 Only one study was included 
in a Cochrane meta-analysis of randomised controlled 
trials investigating coffee caffeine consumption on 
birth weight, preterm birth, and small for gestational 
age, and none of the outcomes reached significance.86
There is also consistency in associations between 
high versus low coffee consumption in pregnancy and 
a higher risk of childhood leukaemia (odds ratio 1.57, 
95% confidence interval 1.16 to 2.11)87 and any versus 
no consumption (1.44, 1.07 to 1.92).88 89
Heterogeneity of included studies
We were able to re-analyse by random effects, 83% 
of comparisons for high versus low and 79% for any 
versus none, but none for one extra cup a day. About 
40% of the 83 meta-analyses that we re-analysed 
had significant heterogeneity, and 90% of these 
had an I2 >50%. The individual studies within each 
meta-analysis varied by many factors, including 
the geography and ethnicity of the population of 
interest, the type of coffee consumed, the method of 
ascertainment of coffee consumption, the measure of 
coffee exposure, duration of follow-up, and outcome 
assessment. For the 54 that we were unable to re-
analyse, 19% had significant heterogeneity, and 27% 
of meta-analyses did not publish heterogeneity for the 
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studies included in the specific exposure comparison. 
Only four studies that we were unable to re-analyse 
used a fixed effects model.
Publication bias of included studies
We performed Egger’s regression test in only 40% of the 
meta-analyses in our reanalysis because the remaining 
60% contained insufficient numbers of studies. In 
those that we reanalysed, 20% had statistical evidence 
of publication bias. This included high versus low 
comparisons for type 2 diabetes (P=0.049),21 stroke 
(P=0.09),19 gastro-oesophageal reflux disease 
(P=0.04),64 bladder cancer (P<0.01),39 endometrial 
cancer (P=0.03),40 and hip fracture (P=0.02),72 and in 
the meta-analysis of randomised controlled trials for 
total cholesterol (P<0.01). For meta-analyses that we 
were unable to reanalyse, none reported significant 
publication bias or they did not conduct or publish 
a statistical test for publication bias for the specific 
exposure comparison. This could have been in part 
because of low number of studies included in the 
pooling. It is possible, however, that unmeasured 
publication bias exists in many of the summary 
estimates we have presented and not assessed.
AMSTAR and GRADE classification of included 
studies
The median AMSTAR score achieved across all studies 
was 5 out of 11 (range 2-9, interquartile range 5-7). 
Eleven studies were downgraded on method of meta-
analysis because they used a fixed, rather than random 
effects, model. Appendix 3 provides a breakdown of 
AMSTAR scores for studies representing each outcome. 
In terms of quality of evidence for each outcome, about 
25% were rated as being of “low” and 75% as “very 
low” quality with the GRADE classification. Even the 
meta-analyses of randomised controlled trials were 
graded as low quality of evidence because of risk of 
bias, inconsistency, or imprecision. Only outcomes 
identified as having a significant dose-response 
effect, or large magnitude of effect, without significant 
other biases reached a GRADE classification of “low” 
compared with the majority rating of “very low.” 
Appendix 4 shows a breakdown of GRADE scores for 
studies representing each outcome. 
discussion
Principal findings and possible explanations
Coffee consumption is more often associated with 
benefit than harm for a range of health outcomes 
across multiple measures of exposure, including high 
versus low, any versus none, and one extra cup a day. 
Exposure to coffee has been the subject of numerous 
meta-analyses on a diverse range of health outcomes. 
We carried out this umbrella review to bring this 
existing evidence together and draw conclusions for 
the overall effects of coffee consumption on health. 
We identified 201 meta-analyses of observational 
research with 67 unique outcomes and 17 meta-
analyses of randomised controlled trials with nine 
unique outcomes.
The conclusion of benefit associated with 
coffee consumption was supported by significant 
associations with lower risk for the generic outcomes 
of all cause mortality,28 cardiovascular mortality,28 
and total cancer.38 Consumption was associated 
with a lower risk of specific cancers, including 
prostate cancer,39 44 90 endometrial cancer,39 40 91 
melanoma,41 45 non-melanoma skin cancer,42 and 
liver cancer.43 Consumption also had beneficial 
associations with metabolic conditions including type 
2 diabetes,21 65 metabolic syndrome,26 gallstones,25 
gout,67 and renal stones66 and for liver conditions 
including hepatic fibrosis,63 cirrhosis,9 63 cirrhosis 
mortality,9 and chronic liver disease combined.43 The 
beneficial associations between consumption and 
liver conditions stand out as consistently having the 
highest magnitude compared with other outcomes 
across exposure categories. Finally, there seems to be 
beneficial associations between coffee consumption 
and Parkinson’s disease,22 76 77 depression,78 79 and 
Alzheimer’s disease.80
Overall, there is no consistent evidence of harmful 
associations between coffee consumption and health 
outcomes, except for those related to pregnancy 
and for risk of fracture in women. After adjustment 
for smoking, consumption in pregnancy seems to 
be associated with harmful outcomes related to low 
birth weight,82 preterm birth,83 and pregnancy loss.23 
These associations were seen in subgroup analyses 
from articles investigating total caffeine exposure, 
which showed similar associations, and from a 
single meta-analysis for each outcome. There were 
also harmful associations between consumption and 
congenital malformations, though these did not reach 
significance.85 The half life of caffeine is known to 
double during pregnancy,92 and therefore the relative 
dose of caffeine from equivalent per cup consumption 
will be much higher than consumption outside 
pregnancy. Caffeine is also known to easily cross the 
placenta,93 and activity of the caffeine metabolising 
enzyme, CYP1A2, is low in the fetus, resulting in 
prolonged fetal exposure to caffeine.94 Though we 
found no significant associations between coffee 
exposure and neural tube defects,84 for this outcome, 
all bar one of the included studies were of case-control 
design and therefore prone to recall bias. Maternal 
exposure to coffee had a harmful association with 
acute leukaemia of childhood,87-89 but evidence for 
this also came from case-control studies.
The effect of the association between coffee 
consumption and risk of fracture was modified by 
sex. While there was no overall significant association 
with risk, the most recent meta-analyses found a 14% 
increased risk for high versus low consumption70 
and 0.6% increased risk for one extra cup a day71 
in women. Conversely, in men consumption was 
beneficially associated with a lower risk of fracture. 
Caffeine has been proposed as the component of 
coffee linked to the increased risk in women, with 
potential influence on calcium absorption95 and 
bone mineral density.96 A recent comprehensive 
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systematic review of the health effects of caffeine, 
however, concluded, with regard to bone health, that 
a caffeine intake of 400 mg/day (about four cups of 
coffee) was not associated with adverse effects on the 
risk of fracture, falls, bone mineral density, or calcium 
metabolism.97 There is limited evidence at higher 
intakes of caffeine to draw firmer conclusions. Notably, 
many of the studies included in the meta-analyses 
of coffee consumption and risk of fracture did not 
adjust for important confounders such as body mass 
index (BMI), smoking, or intakes of calcium, vitamin 
D, and alcohol. Some studies suggest that caffeine 
consumption is associated only with a lower risk of 
low bone mineral density in women with inadequate 
calcium intake,98 and that only a small amount of milk 
added to coffee would be needed to offset any negative 
effects on calcium absorption.95 The type of coffee 
consumed might therefore be an important factor. 
Coffee and caffeine have also been linked to oestrogen 
metabolism in premenopausal women99 and increased 
concentrations of sex hormone binding globulin 
(SHBG) in observational research of postmenopausal 
women.100 The increased globulin concentration was 
associated with lower concentrations of unbound 
testosterone but not unbound oestradiol.100 Low 
concentrations of oestradiol and high concentrations 
of sex hormone binding globulin are known to be 
associated with risk of fracture.101 102 An effect of 
coffee consumption on sex hormone binding globulin, 
however, has not been supported in small scale 
randomised controlled trials.103 Coffee has been 
shown to be beneficially associated with oestrogen 
receptor negative, but not positive, breast cancer.56 
There is consistent evidence, however, to suggest 
that coffee consumption is associated with a lower 
risk of endometrial cancer40 and no clear evidence 
for associations with ovarian cancer.39 53 The effect 
of coffee consumption on endogenous sex hormones 
could therefore be beneficial for some hormone 
dependent cancers but increase the risk of fracture 
in women with inadequate dietary calcium98 or with 
multiple risk factors for osteoporosis.104
When meta-analyses have suggested associations 
between coffee consumption and higher risk of other 
diseases, such as lung cancer, this can largely be 
explained by inadequate adjustment for smoking. 
Smoking is known to be positively associated with 
coffee consumption105 and with many health outcomes 
and could act as both a confounder and effect modifier. 
Galarraga and Boffetta examined the possible 
confounding by smoking in two ways in their recent 
meta-analysis47 of coffee consumption and risk of lung 
cancer. Firstly, they performed the meta-analysis in 
those who had never smoked and detected no harmful 
association. Next, they performed the meta-analysis 
in only those studies that adjusted for smoking, and 
the magnitude of the apparent harmful association 
was reduced and was no longer significant. It is 
likely that residual confounding by smoking, despite 
some adjustment, can explain this apparent harmful 
association. A similar pattern was seen in stratification 
by smoking for coffee consumption and mortality 
from cancer in the recent meta-analysis by Grosso 
and colleagues.28 The authors highlighted the positive 
association between coffee consumption and smoking 
and concluded that residual confounding by smoking 
was the likely explanation.
For randomised controlled trials, coffee has been 
given as an intervention for only short durations and 
limited to a small number of outcomes, including blood 
pressure, lipid profiles, and one trial in pregnancy. 
There does seem to be consistent evidence for small 
increases in concentrations of total cholesterol, low 
density lipoprotein cholesterol, and triglyceride in 
meta-analyses of randomised controlled trials, and this 
is believed to be caused by the action of diterpenes.106 
The method of preparation is an important factor as 
instant and filtered coffee contain negligible amounts 
of diterpenes compared with espresso, with even 
higher amounts in boiled and cafetière coffee.106 In the 
meta-analysis we included in our review, the effect of 
filtered coffee consumption on lipids was negligible or 
failed to reach significance compared with unfiltered 
coffee. Studies also suggest, however, that the dose 
of diterpenes needed to cause hypercholesterolaemia 
is likely to be much higher than the dose needed for 
beneficial anticarcinogenic effects.107 For unfiltered 
coffee, the clinical relevance of such small increases in 
total cholesterol, low density lipoprotein cholesterol, 
and triglyceride due to coffee are difficult to extrapolate, 
especially as coffee consumption does not seem to be 
associated with adverse cardiovascular outcomes, 
including mortality after myocardial infarction.30 
Changes in the lipid profile associated with coffee also 
reversed with abstinence.106
When dose-response analyses have been 
conducted and when these have suggested non-
linearity—for example in all cause mortality, 
cardiovascular disease mortality, cardiovascular 
disease, and heart failure—summary estimates 
indicate that the largest relative risk reduction is 
associated with intakes of three to four cups a day. 
Importantly, increase in consumption beyond this 
intake does not seem to be associated with increased 
risk of harm, rather the magnitude of the benefit 
is reduced. In type 2 diabetes, despite significant 
non-linearity, relative risk reduced sequentially 
from one through to six cups a day. Estimates from 
higher intakes are likely to include a smaller number 
of participants, and this could be reflected in the 
imprecision observed for some outcomes at these 
levels of consumption.
Coffee contains a complex mixture of bioactive 
compounds with plausible biological mechanisms for 
benefiting health. It has been shown to contribute a 
large proportion of daily intake of dietary antioxidant, 
greater than tea, fruit, and vegetables.108 Chlorogenic 
acid is the most abundant antioxidant in coffee; though 
it is degraded by roasting, alternative antioxidant 
organic compounds are formed.109 Caffeine also has 
significant antioxidant effects. The diterpenes, cafestol 
and kahweol, induce enzymes involved in carcinogen 
RESEARCH
12 doi: 10.1136/bmj.j5024 | BMJ 2017;359:j5024 | the bmj
detoxification and stimulation of intracellular 
antioxidant defence,107 contributing towards an 
anticarcinogenic effect. These antioxidant and anti-
inflammatory effects are also likely to be responsible 
for the mechanism behind the beneficial associations 
between coffee consumption and liver fibrosis, 
cirrhosis, and liver cancer110 that our umbrella review 
found had the greatest magnitude of effect compared 
with other outcomes. Additionally, caffeine could have 
direct antifibrotic effects by preventing hepatic stellate 
cell adhesion and activation.111
Decaffeinated coffee is compositionally similar 
to caffeinated coffee apart from having little or no 
caffeine.112 In our umbrella review we identified 16 
unique outcomes for associations with decaffeinated 
coffee. Decaffeinated coffee was beneficially associated 
with all cause and cardiovascular mortality in a 
non-linear dose-response, with summary estimates 
indicating the largest relative risk reduction at intakes 
of two to four cups a day and of similar magnitude to 
caffeinated coffee. Marginal benefit in the association 
between decaffeinated coffee and cancer mortality did 
not reach significance. The associations between high 
versus low consumption of decaffeinated coffee and 
lower risk of type 2 diabetes21 and endometrial cancer40 
were of a similar magnitude to total or caffeinated 
coffee, and there was a small beneficial association 
between decaffeinated coffee and lung cancer.48 The 
other outcomes investigated for decaffeinated coffee 
showed no significant associations, though it should 
be noted that meta-analyses of consumption would 
have much lower power to detect an effect. Importantly, 
there were no convincing harmful associations between 
decaffeinated coffee and any health outcome. People 
who drink decaffeinated coffee might be different 
from those who drink caffeinated coffee, and most 
coffee assessment tools do not adequately account for 
people who might have switched from caffeinated to 
decaffeinated coffee.113
Strengths and weaknesses and in relation to other 
studies
The umbrella review has systematically summarised 
the current evidence for coffee consumption and all 
health outcomes for which a previous meta-analysis 
had been conducted. It used systematic methods that 
included a robust search strategy of four scientific 
literature databases with independent study selection 
and extraction by two investigators. When possible, 
we repeated each meta-analysis with a standardised 
approach that included the use of random effects 
analysis and produced measures of heterogeneity and 
publication bias to allow better comparison across 
outcomes. We also used standard approaches to 
assess quality of methods (AMSTAR) and quality of the 
evidence (GRADE).
AMSTAR has good evidence of validity and 
reliability.13 The AMSTAR score assisted us in 
identifying the highest quality of evidence for each 
outcome. It also allows judgment regarding quality of 
the meta-analysis presented for each outcome. A high 
AMSTAR score for a meta-analysis, however, does not 
equate to high quality of the original studies, and the 
assessment and use of quality scoring of the original 
studies accounts for only two of 11 possible AMSTAR 
points. Additionally, appropriate method of analysis, 
accounting for one score of quality, can be subjective. 
We downgraded any meta-analysis that used a fixed 
effects model irrespective of heterogeneity for reasons 
discussed previously. The AMSTAR system, however, 
allows only a 1 point loss for a poor analysis technique 
and would not capture multiple issues within an 
individual meta-analysis.
One recurring issue for many of the included meta-
analyses was the assumption that summary relative 
risk could be pooled from a combination of odds ratio, 
relative rates, and hazard ratios so that they could 
combine studies with differing measures. Statistically, 
the odds ratio is similar to the relative risk when the 
outcome is uncommon114 but will always be more 
extreme.114 Similarly, for rare events, relative rates 
and hazard ratios are similar to the relative risk 
when censoring is uncommon or evenly distributed 
between exposed and unexposed groups.114 Many 
meta-analyses stated their assumption but included 
insufficient information to allow us to judge the 
suitability of the pooling. Notably, only one meta-
analysis produced a summary statistic with hazard 
ratios.53 We did not downgrade the AMSTAR score 
when this assumption had been made, and we did 
not downgrade meta-analyses for failing to consider 
uncertainty in variance estimates as this was 
universally unstated.115 Furthermore, the computation 
of dose-response meta-analyses should use methods 
that account for lack of independence in comparisons 
(same unexposed group), such as those proposed by 
Greenland and Longnecker.116 Reassuringly, most 
dose-response meta-analyses we included in our 
summary tables cited this method.
Most of the studies we included were meta-analyses 
of observational studies. One strength of the umbrella 
review was the inclusion only of cohort studies, or 
subgroup analyses of cohort studies when available, in 
preference to summary estimates from a combination 
of study designs. In meta-analyses that we were 
unable to re-analyse and when subgroup analysis did 
not allow the disentanglement of study design, the 
presented results were from the combined estimates of 
all included studies. Observational research, however, 
is low quality in the hierarchy of evidence and with 
GRADE classification most outcomes are recognised 
as having very low or low quality of evidence where a 
dose-response relation exists. Large effect sizes of >2 or 
<0.5 can permit observational evidence to be upgraded 
in GRADE, and only the association between high 
versus low coffee consumption and both liver cancer43 
and chronic liver disease43 reached this magnitude. 
In fact, associations between coffee consumption 
and liver outcomes consistently had larger effect sizes 
than other outcomes across exposure categories. Our 
reanalysis did not change our GRADE classification for 
any outcome.
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A possible limitation of our review was that we 
did not reanalyse any of the dose-response meta-
analyses as the data needed to compute these were not 
generally available in the articles. We did not review 
the primary studies included in each of the meta-
analyses that would have facilitated this. We decided 
that reanalysing the dose-response data was unlikely 
to result in changes to the GRADE classification. In our 
reanalysis of the comparison of high versus low and 
any versus no coffee, we used data available in the 
published meta-analyses and therefore assumed the 
exposure and estimate data for component studies had 
been published accurately.
We were able to produce estimates for publication 
bias using Egger’s test for meta-analyses containing 10 
or more studies.17 Egger’s test is not recommended with 
fewer studies. We were unable to conduct alternative 
tests, such as Peters’ test,117 which is more appropriate 
for binary outcomes, because this needed cases and 
non-cases for each level of exposure and this detail 
was largely unavailable in the meta-analyses. We did 
not calculate excess significance tests, which attempt 
to detect reporting bias by comparing the number of 
studies that have formally significant results with the 
number expected, based on the sum of the statistical 
powers from individual studies, and using an effect 
size equal to the largest study in the meta-analysis.118 
Excess significance tests, however, have not been 
fully evaluated and are not therefore currently 
recommended as an alternative to traditional tests of 
publication bias.119 Further bias in methods could have 
occurred if the same meta-analysis authors conducted 
multiple meta-analyses for different health outcomes. 
There was also an overlap of health outcomes with 
data from the same original cohort studies. While 
the associations for different health outcomes were 
statistically independent, any methodological issues 
in design or conduct of the original cohorts could 
represent repeated bias filtering through the totality of 
evidence.
The beneficial association between coffee 
consumption and all cause mortality highlighted in 
our umbrella review is in agreement with two recently 
published cohort studies. The first was a large cohort 
study of 521 330 participants followed for a mean 
period of 16 years in 10 European countries, during 
which time there were 41 693 deaths.120 The highest 
quarter of coffee consumption, when compared with 
no coffee consumption, was associated with a 12% 
lower risk of all cause mortality in men (hazard ratio 
0.88, 95% confidence interval 0.82 to 0.95) and a 
7% lower risk in women (0.93, 0.82 to 0.95). Coffee 
was also beneficially associated with a range of 
cause specific mortality, including mortality from 
digestive tract disease in men and women and from 
circulatory and cerebrovascular disease in women. 
The study was able to adjust for a large number of 
potential confounding factors, including education, 
lifestyle (smoking, alcohol, physical activity), dietary 
factors, and BMI. Importantly, the study found no 
harmful associations between coffee consumption 
and mortality, apart from the highest quarter versus 
no coffee consumption and increased risk of mortality 
from ovarian cancer (1.31, 1.07 to 1.61). No prevailing 
hypothesis was cited. In our umbrella review, high 
versus low coffee consumption was associated with an 
8% increased risk and one extra cup a day with a 2% 
increased risk of incident ovarian cancer, but neither 
reached significance.
In the second study, a North American cohort of 
185 855 participants was followed for a mean duration 
of 16 years, during which 58 397 participants died.121 
After adjustment for smoking and other factors, 
consumption of four or more cups of coffee a day was 
associated with an 18% lower risk of mortality (hazard 
ratio 0.82, 95% confidence interval 0.78 to 0.87). The 
findings were consistent across subgroups stratified 
by ethnicity that included African Americans, 
Japanese Americans, Latino, and white populations. 
Associations were also similar in men and women. 
Mortality from heart disease, cancer, chronic lower 
respiratory disease, stroke, diabetes, and kidney 
disease was also beneficially associated with coffee 
consumption. Importantly, no harmful associations 
were identified. Subtypes of cancer mortality, however, 
were not published.
Many of the associations between coffee 
consumption and health outcomes, which are 
largely from cohort studies, could be affected by 
residual confounding. Smoking, age, BMI, and 
alcohol consumption are all associated with coffee 
consumption and a considerable number of health 
outcomes. These relations might differ in magnitude 
and even direction between populations. Residual 
confounding by smoking could reduce a beneficial 
association or increase a harmful association when 
smoking is also associated with an outcome. Coffee 
could also be a surrogate marker for factors that are 
associated with beneficial health such as higher 
income, education, or lower deprivation, which could 
be confounding the observed beneficial associations. 
The design of randomised controlled trials can 
reduce the risk of confounding because the known 
and unknown confounders are distributed randomly 
between intervention and control groups. Mendelian 
randomisation studies can also help to reduce the 
effects of confounding from random distribution of 
confounders between genotypes of known function 
related to the outcome of interest. The association 
between coffee consumption and lower risk of type 
2 diabetes122 and all cause and cardiovascular 
mortality123 was found to have no genetic evidence for 
a causal relation in Mendelian randomisation studies, 
suggesting residual confounding could result in the 
observed associations in other studies. The authors 
point out, however, that the Mendelian randomisation 
approach relies on the assumption of linearity 
between all categories of coffee intake and might 
not capture non-linear differences. The same genetic 
variability in coffee and caffeine metabolism could 
influence the magnitude, frequency, and duration 
of exposure to caffeine and other coffee bioactive 
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compounds. Palatini and colleagues found that the 
risk of hypertension associated with coffee varied 
depending on the CYP1A2 genotype.124 Those with 
alleles for slow caffeine metabolism were at increased 
risk of hypertension compared with those with alleles 
for fast caffeine metabolism.
Bias from reverse causality can also occur in 
observational studies. In case-control studies, 
symptoms from disease might have led people to 
reduce their intake of coffee. When possible, we 
included meta-analyses of cohort studies or cohort 
subgroup analyses in our review as they are less prone 
to this type of bias. Even prospective cohort studies, 
however, can be affected by reverse causality bias, in 
which participants who were apparently healthy at 
recruitment might have reduced their coffee intake 
because of early symptoms of a disease.
Most meta-analyses produced summary effects from 
individual studies that measured coffee exposure 
by number of cups a day. Some individual studies, 
however, used number of times a day, servings a day, 
millilitres a day, cups a week, times a week, cups a 
month, and drinkers versus non-drinkers to measure 
coffee consumption. There is no universally recognised 
standard coffee cup size, and the bioactive components 
of coffee in a single cup will vary depending on the type 
of bean (such as Arabica or Robusta), degree of roasting, 
and method of preparation, including the quantity of 
bean, grind setting, and brew type used. Therefore, 
studies that are comparing coffee consumption by cup 
measures could be comparing ranges of exposures. 
The range of number of cups a day classified as both 
high and low consumption from different individual 
studies varied substantially for inclusion in each 
meta-analysis. High versus low consumption was the 
most commonly used measure of exposure. Consistent 
results across meta-analyses and categories of 
exposure, however, suggest that measurement of cups 
a day produces a reasonable differential in exposure. 
Additionally, any misclassification in exposure is likely 
to be non-differential and would more likely dilute 
any risk estimate rather than strengthen it, pushing it 
towards the null.
The inclusion criteria for the umbrella review meant 
that some systematic reviews were omitted when 
they did not do any pooled analysis. Meta-analyses 
in relation to coffee consumption, however, have 
been done on most health outcomes for which there 
is also a systematic review, except for respiratory 
outcomes125 and sleep disturbance.126 There could 
also be important well conducted studies that have 
assessed coffee consumption in relation to outcomes 
for which no investigators have attempted to perform 
any combined review, whether pooling the estimate or 
not. Additionally, the umbrella review has investigated 
defined health outcomes rather than physiological 
outcomes. This means there could be physiological 
effects of coffee such as increased heart rate, 
stimulation of the central nervous system, and feelings 
of anxiety that have not been captured in this review 
and must be considered should individuals be taking 
drugs that have similar physiological effects or in those 
trying to avert anxiety.
Despite our broad inclusion criteria, we identified 
only one meta-analysis that focused on a population 
of people with established disease. This was a meta-
analysis of two small cohort studies investigating risk of 
mortality in people who had experienced a myocardial 
infarction.30 In contrast, most meta-analyses estimated 
the association between coffee consumption and 
outcomes in general population cohorts rather than 
those selected by pre-existing disease. Our summation 
of the existing body of evidence should therefore be 
viewed in this context and suggests that the association 
of coffee consumption in modifying the natural history 
of established disease remains unclear.
We extracted details of conflicts of interest and 
funding declarations from articles selected in the 
umbrella review. Only one article declared support 
from an organisation linked to the coffee industry, and 
a second article stated that their authors contributed 
to the same organisation. Neither of these articles 
was selected to represent the respective outcome in 
the summary figures, and all references for studies 
not included in the summary tables are available 
on request. We did not review the primary studies 
included in each meta-analysis and cannot comment 
on whether any of these studies were funded by 
organisations linked to the coffee industry. 
Conclusions and recommendations
Coffee consumption has been investigated for 
associations with a diverse range of health outcomes. 
This umbrella review has systematically assimilated 
this vast amount of existing evidence where it has been 
published in a meta-analysis. Most of this evidence 
comes from observational research that provides 
only low or very low quality evidence. Beneficial 
associations between coffee consumption and liver 
outcomes (fibrosis, cirrhosis, chronic liver disease, and 
liver cancer) have relatively large and consistent effect 
sizes compared with other outcomes. Consumption is 
also beneficially associated with a range of other health 
outcomes and importantly does not seem to have 
definitive harmful associations with any outcomes 
outside of pregnancy. The association between 
consumption and risk of fracture in women remains 
uncertain but warrants further investigation. Residual 
confounding could explain some of the observed 
associations, and Mendelian randomisation studies 
could be applied to a range of outcomes, including risk 
of fracture, to help examine this issue. Randomised 
controlled trials that change long term behaviour, and 
with valid proxies of outcomes important to patients, 
could offer more definitive conclusions and could be 
especially useful in relation to coffee consumption 
and chronic liver disease. Reassuringly, our analysis 
indicates that future randomised controlled trials 
in which the intervention is increasing coffee 
consumption, within usual levels of intake, possibly 
optimised at three to four cups a day, would be unlikely 
to result in significant harm to participants. Pregnancy, 
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or risk of pregnancy, and women with higher a risk of 
fracture, however, would be justified exclusion criteria 
for participation in a coffee treatment study.
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